LIXTE And NKI Launch Pre-Clinical Study To Target Early Cancer Cells With LB-100

LIXTE Biotechnology Holdings, Inc. has announced a new pre-clinical study in partnership with the Netherlands Cancer Institute (NKI) to determine if LB-100, the company’s proprietary compound, can eliminate "initiated" mutated cells that may later develop into cancer.

As people age, mutations linked to cancer can accumulate in cells. While these initiated cells appear normal, they may serve as reservoirs for pre-malignant conditions. Data from LIXTE’s ongoing collaboration with NKI suggests that LB-100 activates oncogenic signalling, which negatively impacts cancer cells. The upcoming animal study will test whether LB-100 can specifically target and eliminate RAS-mutant-initiated cells, potentially reducing cancer risk in ageing individuals.

“In addition to our ongoing clinical trials in ovarian and colorectal cancer, this study represents a new opportunity in cancer prevention. Thus far in our Phase 1 clinical trials, LB-100 has shown patient tolerance, with little toxicity, making it a promising candidate as a broad and effective cancer prevention modality,” said Bas van der Baan, LIXTE’s Chief Executive Officer. 

Dr. René Bernards, a renowned expert in molecular carcinogenesis and a Senior Staff Scientist at NKI, will lead this research. Dr. Bernards, who is also on LIXTE’s Board of Directors, aims to explore LB-100’s potential role in cancer prevention by disrupting the early-stage development of malignant cells.